#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Megha Ranjan Email
Project Director . Cereno
Mölndal,
Locationm***********@cerenoscientific.com
Primary EmailHow to contact Megha Ranjan
Join and see Megha's contact info for free!Current Roles
Employees:
34Revenue:
$5.3MAbout
Cereno Scientific is a leading clinical stage biotech company within cardiovascular epigenetic modulation. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. A clinical phase II study program for CS1 in PAH has obtained a US FDA granted orphan drug designation (ODD) status. In addition, Cereno has a preclinical HDAC inhibitor development program targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca's BioVenture Hub, Sweden, and has an office in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.Cereno Address
Pepparedsleden 1Mölndal, null